Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

7,852 total articles

S&P upgrades SiriusPoint’s Insurance Subsidiaries to ‘A’ based on consistent robust earnings and strength of capital position

S&P upgrades SiriusPoint’s Insurance Subsidiaries to ‘A’ based on consistent robust earnings and strength of capital position

SiriusPoint Ltd has received an upgrade from S&P Global Ratings on its core insurance operating subsidiaries to 'A' from 'A-', marking the company's third upgrade this year. The holding company rating was also raised to 'BBB+' from 'BBB' with a stable outlook. The upgrades are attributed to SiriusPoint's consistent underwriting performance, de-risk…

Table for Mom: OpenTable Launches Mother’s Day Dining Trends and Canada’s Top 100 Brunch and Lunch Restaurants for 2026

Table for Mom: OpenTable Launches Mother’s Day Dining Trends and Canada’s Top 100 Brunch and Lunch Restaurants for 2026

OpenTable, part of Booking Holdings, Inc., announced its annual Top 100 Brunch and Lunch Restaurants in Canada for 2026 and shared consumer trends for Mother’s Day dining, revealing that 65% of Canadians consider dining out an important part of their celebration. The data highlights evolving celebration styles including solo dining, larger family g…

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

Revolution Medicines announced that detailed results from its pivotal Phase 3 RASolute 302 clinical trial of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma patients, will be presented at the 2026 ASCO Annual Meeting. The topline data showed statistically significant and cli…

Alexander’s Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

Alexander’s Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

Alexander's, Inc., a New York City-based real estate investment trust, will release its Q1 2026 earnings on May 4, 2026, before market open. Vornado Realty Trust, the manager of Alexander's operations, will host a conference call on May 5, 2026, discussing quarterly results including those related to Alexander's. The company highlighted typical for…

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond Therapeutics announced multiple presentations at the 2026 ASCO Annual Meeting showcasing Phase 2 data of their brain-penetrant EGFR inhibitor, Silevertinib, in non-small cell lung cancer (NSCLC) and glioblastoma (GBM) patients. Early data indicate promising efficacy and safety profiles, including a 60% objective response rate in front…

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

Regeneron Pharmaceuticals reported positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy targeting complement factor 5 (C5), demonstrating rapid, deep, and sustained disease control in adults with generalized myasthenia gravis (gMG). The trial met primary and key secondary endpoints at 24 weeks, showing significant …

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals announced that an abstract highlighting results from Part 1 of their MUIR trial, testing azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, has been accepted for presentation at the ASCO 2026 Annual Meeting. Azenosertib, a first-in-class WEE1 inhibitor, is being developed as a biomarker-driven…

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics N.V. announced that four abstracts from its clinical cell therapy and bispecific T-cell engager pipeline have been selected for oral presentations at the 2026 ASCO Annual Meeting. Data highlights include Phase 1b results of anzu-cel in melanoma, updated Phase 1a/b data for second-generation IMA203CD8 in gynecologic cancers, findings on PRA…

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics announced that early results from their first-in-human Phase 1 trial of the WEE1 inhibitor APR-1051 in advanced solid tumor patients have been accepted for presentation at the 2026 ASCO Annual Meeting. This milestone highlights progress in developing targeted therapies for biomarker-defined cancers and underscores the company's f…

IP Strategy Announces Reverse Stock Split

IP Strategy Announces Reverse Stock Split

IP Strategy Holdings, Inc. has announced a 1-for-20 reverse stock split of its common stock effective April 23, 2026, aimed at complying with Nasdaq's minimum bid price requirements and improving stock liquidity. The reverse split will adjust shares and outstanding warrants proportionately without affecting authorized shares or shareholder rights e…

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Cellectar Biosciences announced that a subset of data from their CLOVER WaM clinical trial involving iopofosine I-131 was accepted for presentation at the 2026 American Society of Clinical Oncology Annual Meeting. The data focuses on relapsed/refractory Waldenström macroglobulinemia (WM) patients who have progressed after treatment with BTK inhibit…

Progress Software Releases 2025 Corporate Social Responsibility Report, Underscoring Global Commitment to Giving Back

Progress Software Releases 2025 Corporate Social Responsibility Report, Underscoring Global Commitment to Giving Back

Progress Software released its 2025 Corporate Social Responsibility report showcasing a strong commitment to employee development, community engagement, and environmental sustainability. The report details expanded professional growth programs, support for global charitable initiatives especially in STEM education, and steps toward enhanced environ…

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine announced that it will present new data from the RALLY-MF Phase 2 trial of DISC-0974, an investigational treatment for anemia in myelofibrosis patients, at the American Society of Clinical Oncology Annual Meeting in June 2026. Initial trial results showed unprecedented anemia response rates in a hard-to-treat population, with updated …

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Cardiff Oncology announced it will present updated interim results from its Phase 2 trial evaluating onvansertib in combination with standard chemotherapy regimens for first-line treatment of RAS-mutated metastatic colorectal cancer. The presentation at ASCO 2026 underscores onvansertib's potential as a novel oral PLK1 inhibitor addressing a signif…

SoundHound AI To Acquire LivePerson, Combining Proprietary Voice Agentic AI and Digital Messaging to Create a World Leading End-to-End Omnichannel Conversational AI Platform

SoundHound AI To Acquire LivePerson, Combining Proprietary Voice Agentic AI and Digital Messaging to Create a World Leading End-to-End Omnichannel Conversational AI Platform

SoundHound AI (Nasdaq: SOUN) announced it will acquire LivePerson (Nasdaq: LPSN) in a strategic transaction combining their voice AI and digital messaging capabilities. The deal aims to create a comprehensive, end-to-end omnichannel conversational AI platform serving over 25 Fortune 100 companies, with expanded vertical reach and significant revenu…

Edible Garden Wins Major New Fresh-Cut Herb Program at Target Stores

Edible Garden Wins Major New Fresh-Cut Herb Program at Target Stores

Edible Garden AG Incorporated announced a significant expansion of its fresh-cut herb supply to Target stores, increasing its retail footprint and expected to boost revenue growth. The company emphasizes its advanced controlled environment agriculture technology, sustainable operations, and patented innovations in farming and displays. This expande…

Silynxcom Secures Approximately $500,000 Order for Advanced Tactical Protective Systems from New Asian Military Customer

Silynxcom Secures Approximately $500,000 Order for Advanced Tactical Protective Systems from New Asian Military Customer

Silynxcom Ltd., a manufacturer of ruggedized tactical communication headsets, announced it received a $500,000 purchase order from a new military customer in Asia. The order furthers the company's expansion into the Asian defense market with their advanced in-ear tactical headset systems featuring superior noise reduction, 'hear-thru' technology, a…

SEALSQ Advances Post-Quantum Cryptography (PQC) in Silicon to Counter AI-Driven Threats Following Anthropic’s Mythos Breakthrough

SEALSQ Advances Post-Quantum Cryptography (PQC) in Silicon to Counter AI-Driven Threats Following Anthropic’s Mythos Breakthrough

SEALSQ Corp announces significant advancements in embedding Post-Quantum Cryptography (PQC) directly into semiconductor hardware to counter emerging AI-driven cybersecurity threats, highlighted by recent breakthroughs like Anthropic's Claude Mythos. The company emphasizes that hardware-based quantum-resistant cryptography offers superior protection…